Barger B O, Acton R T, Koopman W J, Alarcón G S
Arthritis Rheum. 1984 Jun;27(6):601-5. doi: 10.1002/art.1780270601.
An increase in the frequency of DR3 in rheumatoid arthritis (RA) patients exhibiting toxic reactions to chrysotherapy has been reported in several studies of white patients. This study was designed to compare DR antigen frequencies in local white RA patients undergoing chrysotherapy with their response to treatment. The results from our sample of RA patients (n = 148) confirm the fact that there is increased frequency of DR3 in patients who develop toxic reactions to gold therapy, as reported in other studies of white patients. The DR3 increase was attributable to those gold-treated patients who developed proteinuria, and was not observed in patients who developed skin toxicity. Interestingly, the associations were not as strong as those found in other reports. Only 21.1% of the patients with DR3 manifested toxic reactions overall, with only one-third of the patients with proteinuria being DR3 positive. There was also an association of toxicity, albeit not significant, with a decreased frequency of DR2, which is consistent with the suggestion that this phenotype may protect against adverse reactions to gold treatment. These results suggest that while DR3 is significantly associated with adverse response to gold treatment, the relationship is not as strong as that previously reported. Explanation of these differences remains to be elucidated.
在几项针对白人患者的研究中,已有报告称,对金疗法产生毒性反应的类风湿关节炎(RA)患者中,DR3频率增加。本研究旨在比较接受金疗法的当地白人RA患者的DR抗原频率与其治疗反应。我们的RA患者样本(n = 148)的结果证实了这样一个事实,即正如其他白人患者研究中所报告的那样,对金疗法产生毒性反应的患者中DR3频率增加。DR3增加归因于那些出现蛋白尿的金治疗患者,而在出现皮肤毒性的患者中未观察到。有趣的是,这种关联并不像其他报告中发现的那样强烈。总体而言,只有21.1%的DR3患者表现出毒性反应,只有三分之一的蛋白尿患者DR3呈阳性。毒性与DR2频率降低也存在关联,尽管不显著,这与该表型可能预防金治疗不良反应的观点一致。这些结果表明,虽然DR3与金治疗的不良反应显著相关,但这种关系并不像先前报告的那样强烈。这些差异的解释仍有待阐明。